Medpace alternatives
Companies similar to Medpace on cro.directory, ranked by shared capabilities and locations focusing on Radiopharmaceutical, Vaccine, Cell Therapy, and Gene Therapy. Below are the top 10 cros with overlapping structured profile data.
Shares In Vivo PK / PD Studies, In Vivo Efficacy Models, Preclinical In Vivo Studies, and Preclinical In Vitro Studies.
Shares CNS Specialty Services, China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, and EU EMA Regulatory Strategy.
Shares In Vivo PK / PD Studies, In Vivo Efficacy Models, Preclinical In Vivo Studies, and Preclinical In Vitro Studies.
Shares Ligand-Binding Bioanalysis (Large Molecule), CNS Specialty Services, China NMPA Regulatory Strategy, and Japan PMDA Regulatory Strategy.
Shares In Vivo PK / PD Studies, Ligand-Binding Bioanalysis (Large Molecule), EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares In Vivo PK / PD Studies, In Vivo Efficacy Models, Preclinical In Vivo Studies, and Preclinical In Vitro Studies.
Shares CNS Specialty Services, EU EMA Regulatory Strategy, US FDA Regulatory Strategy, and Virology Services.
Shares Ligand-Binding Bioanalysis (Large Molecule), China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, and EU EMA Regulatory Strategy.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
How we pick similar companies: alternatives similarity uses shared services, modalities, locations, and site-specific capability fields — not sponsorship. Missing fields stay blank. Data comes from structured directory profiles.
Interactive comparison
Lock shared capabilities to filter peers. Locked views are not indexed — the canonical page stays unlocked.
Capability locks
- Tigermed
Shares In Vivo PK / PD Studies, In Vivo Efficacy Models, Preclinical In Vivo Studies, and Preclinical In Vitro Studies.
- IQVIA
Shares CNS Specialty Services, China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, and EU EMA Regulatory Strategy.
- Labcorp
Shares In Vivo PK / PD Studies, In Vivo Efficacy Models, Preclinical In Vivo Studies, and Preclinical In Vitro Studies.
- ICON plc
Shares Ligand-Binding Bioanalysis (Large Molecule), CNS Specialty Services, China NMPA Regulatory Strategy, and Japan PMDA Regulatory Strategy.
- Simbec-Orion
Shares In Vivo PK / PD Studies, Ligand-Binding Bioanalysis (Large Molecule), EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Premier Research
Shares In Vivo PK / PD Studies, In Vivo Efficacy Models, Preclinical In Vivo Studies, and Preclinical In Vitro Studies.
- Syneos Health
Shares CNS Specialty Services, EU EMA Regulatory Strategy, US FDA Regulatory Strategy, and Virology Services.
- PPD
Shares Ligand-Binding Bioanalysis (Large Molecule), China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, and EU EMA Regulatory Strategy.
- Fortrea
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
- Novotech
Shares China NMPA Regulatory Strategy, Japan PMDA Regulatory Strategy, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.
Markdown mirror: /alternatives/medpace.md